View Financial HealthVanta Bioscience 배당 및 자사주 매입배당 기준 점검 0/6Vanta Bioscience 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-61.6%자사주 매입 수익률총 주주 수익률-61.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 08Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025공시 • Sep 09Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad IndiaReported Earnings • Aug 02Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024)Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.공시 • Jul 16Vanta Bioscience Limited to Report Second Half, 2025 Results on Jul 19, 2025Vanta Bioscience Limited announced that they will report second half, 2025 results on Jul 19, 2025New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$536k). Market cap is less than US$10m (₹156.5m market cap, or US$1.83m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change).공시 • May 21Vanta Bioscience Limited to Report Q4, 2025 Results on May 30, 2025Vanta Bioscience Limited announced that they will report Q4, 2025 results on May 30, 2025New Risk • May 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹153.6m market cap, or US$1.80m).New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹152.8m market cap, or US$1.79m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).New Risk • Nov 16New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹46m (US$543k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$543k). Market cap is less than US$10m (₹259.9m market cap, or US$3.08m).공시 • Nov 12Vanta Bioscience Limited to Report First Half, 2025 Results on Nov 14, 2024Vanta Bioscience Limited announced that they will report first half, 2025 results on Nov 14, 2024공시 • Sep 13Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad IndiaNew Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹7.2m free cash flow). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 70% per year over the past 5 years. Market cap is less than US$10m (₹351.9m market cap, or US$4.19m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m).Reported Earnings • Jul 25Full year 2024 earnings released: ₹3.67 loss per share (vs ₹10.27 loss in FY 2023)Full year 2024 results: ₹3.67 loss per share (improved from ₹10.27 loss in FY 2023). Revenue: ₹98.3m (up 43% from FY 2023). Net loss: ₹23.2m (loss narrowed 64% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.공시 • Jul 11Vanta Bioscience Limited to Report Second Half, 2024 Results on Jul 17, 2024Vanta Bioscience Limited announced that they will report second half, 2024 results on Jul 17, 2024New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹83m free cash flow). Earnings have declined by 76% per year over the past 5 years. Market cap is less than US$10m (₹360.0m market cap, or US$4.32m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₹103m revenue, or US$1.2m).Board Change • Feb 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 12Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance.공시 • Sep 07Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony Sikh Village, Bowenpally, Secunderabad 500009 Telangana Andhra Pradesh IndiaBoard Change • Sep 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 12New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹70m (US$839k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Revenue is less than US$1m (₹70m revenue, or US$839k). Market cap is less than US$10m (₹371.1m market cap, or US$4.47m).Reported Earnings • Aug 11Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.공시 • Aug 05Vanta Bioscience Limited to Report Second Half, 2023 Results on Aug 10, 2023Vanta Bioscience Limited announced that they will report second half, 2023 results on Aug 10, 2023공시 • Jul 12Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that Ms. Vidisha Rathod has resigned as Company Secretary and Compliance Officer of the Company with immediate effect July 10, 2023, due to her pre-occupations and personal reasons. The Company is in the process of appointing a new Company Secretary. In the interim, Mr. Dopesh Raja Mulakala, Managing Director is being appointed as the Compliance officer of the Company.공시 • May 23Vanta Bioscience Limited to Report Q4, 2023 Results on May 30, 2023Vanta Bioscience Limited announced that they will report Q4, 2023 results on May 30, 2023공시 • Dec 08Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022, at 10:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad 500009 Telangana IndiaBoard Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Sep 16Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that the company has appointed Ms. Vidisha Rathod as company secretary and compliance officer of the company, effective September 15, 2022. Ms. Vidisha Rathod is a qualified company secretary and an associate member of ICSI. She has over 5+ years of rich experience in Secretarial matters. She has previously worked as company secretary with Public Limited Companies like Chrysalis Finance Ltd., Mimanshu Industries Ltd. and Aatash Norcontrol Limited. She has exposure of handling various secretarial and legal matters. She is being appointed as CS and Compliance Officer, effective September 15, 2022 due to the resignation of existing CS. She is not associated with any of the Directors or KMPs of the company.공시 • Sep 04Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance OfficerVanta Bioscience Limited announced the resignation of Mr. Zoheb S Sayani as the Company Secretary and Compliance officer of the Company w.e.f.15.09.2022 due to his pre-occupations.Board Change • Jul 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Jun 28Insider recently bought ₹518k worth of stockOn the 21st of June, Chandra Shekar Simhadri bought around 5k shares on-market at roughly ₹98.64 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Jun 03Full year 2022 earnings released: EPS: ₹0.14 (vs ₹0.71 in FY 2021)Full year 2022 results: EPS: ₹0.14 (down from ₹0.71 in FY 2021). Revenue: ₹101.1m (flat on FY 2021). Net income: ₹882.0k (down 80% from FY 2021). Profit margin: 0.9% (down from 4.5% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹0.71 (vs ₹1.59 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹100.4m (down 29% from FY 2020). Net income: ₹4.50m (down 55% from FY 2020). Profit margin: 4.5% (down from 7.1% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 28% per year.Is New 90 Day High Low • Mar 03New 90-day high: ₹150The company is up 7.0% from its price of ₹140 on 03 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 3.0% over the same period.공시 • Jan 06Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as DirectorVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the Whole Time Director of the company with effect from the close of working hours of January 4, 2021.공시 • Jan 05Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as CEOVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the CEO of the company with effect from the close of working hours of January 04, 2021.Is New 90 Day High Low • Dec 28New 90-day low: ₹124The company is down 31% from its price of ₹180 on 28 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 09New 90-day low: ₹134The company is down 18% from its price of ₹164 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 19% over the same period.공시 • Nov 14Vanta Bioscience Limited Enters into Commercial Agreement with One of the Leading German Testing AgencyVanta Bioscience Limited announced that it has entered into a commercial agreement with one of the leading German Testing agency, wherein the Client has commissioned Vanta Bio to carry out Laboratory Testing Services in Biocompatibility and Analytics. The said agreement is valid for a period of 2 years. This is a major break through for the Company considering its decision to foray into Medical Devices vertical. This is not only an acknowledgement of the technical capabilities of Vanta Bio, but also validation of the world class services being provided by the Company. Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition. Expected to generate a revenue of INR 100 million-INR 150 million approx. over the period of 2 years.Is New 90 Day High Low • Nov 04New 90-day low: ₹148The company is down 6.0% from its price of ₹157 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.Is New 90 Day High Low • Sep 23New 90-day high: ₹170The company is up 32% from its price of ₹129 on 25 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 37% over the same period.공시 • Jun 20Vanta Bioscience Limited to Report Fiscal Year 2020 Results on Jun 30, 2020Vanta Bioscience Limited announced that they will report fiscal year 2020 results on Jun 30, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 540729 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 540729 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Vanta Bioscience 배당 수익률 vs 시장540729의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (540729)n/a시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Life Sciences)0.4%분석가 예측 (540729) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 540729 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 540729 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 540729 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 540729 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:02종가2026/05/21 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vanta Bioscience Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Nov 08Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025
공시 • Sep 09Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India
Reported Earnings • Aug 02Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024)Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
공시 • Jul 16Vanta Bioscience Limited to Report Second Half, 2025 Results on Jul 19, 2025Vanta Bioscience Limited announced that they will report second half, 2025 results on Jul 19, 2025
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$536k). Market cap is less than US$10m (₹156.5m market cap, or US$1.83m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change).
공시 • May 21Vanta Bioscience Limited to Report Q4, 2025 Results on May 30, 2025Vanta Bioscience Limited announced that they will report Q4, 2025 results on May 30, 2025
New Risk • May 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹153.6m market cap, or US$1.80m).
New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹152.8m market cap, or US$1.79m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
New Risk • Nov 16New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹46m (US$543k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$543k). Market cap is less than US$10m (₹259.9m market cap, or US$3.08m).
공시 • Nov 12Vanta Bioscience Limited to Report First Half, 2025 Results on Nov 14, 2024Vanta Bioscience Limited announced that they will report first half, 2025 results on Nov 14, 2024
공시 • Sep 13Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹7.2m free cash flow). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 70% per year over the past 5 years. Market cap is less than US$10m (₹351.9m market cap, or US$4.19m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m).
Reported Earnings • Jul 25Full year 2024 earnings released: ₹3.67 loss per share (vs ₹10.27 loss in FY 2023)Full year 2024 results: ₹3.67 loss per share (improved from ₹10.27 loss in FY 2023). Revenue: ₹98.3m (up 43% from FY 2023). Net loss: ₹23.2m (loss narrowed 64% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
공시 • Jul 11Vanta Bioscience Limited to Report Second Half, 2024 Results on Jul 17, 2024Vanta Bioscience Limited announced that they will report second half, 2024 results on Jul 17, 2024
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹83m free cash flow). Earnings have declined by 76% per year over the past 5 years. Market cap is less than US$10m (₹360.0m market cap, or US$4.32m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₹103m revenue, or US$1.2m).
Board Change • Feb 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 12Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance.
공시 • Sep 07Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony Sikh Village, Bowenpally, Secunderabad 500009 Telangana Andhra Pradesh India
Board Change • Sep 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 12New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹70m (US$839k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Revenue is less than US$1m (₹70m revenue, or US$839k). Market cap is less than US$10m (₹371.1m market cap, or US$4.47m).
Reported Earnings • Aug 11Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
공시 • Aug 05Vanta Bioscience Limited to Report Second Half, 2023 Results on Aug 10, 2023Vanta Bioscience Limited announced that they will report second half, 2023 results on Aug 10, 2023
공시 • Jul 12Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that Ms. Vidisha Rathod has resigned as Company Secretary and Compliance Officer of the Company with immediate effect July 10, 2023, due to her pre-occupations and personal reasons. The Company is in the process of appointing a new Company Secretary. In the interim, Mr. Dopesh Raja Mulakala, Managing Director is being appointed as the Compliance officer of the Company.
공시 • May 23Vanta Bioscience Limited to Report Q4, 2023 Results on May 30, 2023Vanta Bioscience Limited announced that they will report Q4, 2023 results on May 30, 2023
공시 • Dec 08Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022, at 10:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad 500009 Telangana India
Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Sep 16Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that the company has appointed Ms. Vidisha Rathod as company secretary and compliance officer of the company, effective September 15, 2022. Ms. Vidisha Rathod is a qualified company secretary and an associate member of ICSI. She has over 5+ years of rich experience in Secretarial matters. She has previously worked as company secretary with Public Limited Companies like Chrysalis Finance Ltd., Mimanshu Industries Ltd. and Aatash Norcontrol Limited. She has exposure of handling various secretarial and legal matters. She is being appointed as CS and Compliance Officer, effective September 15, 2022 due to the resignation of existing CS. She is not associated with any of the Directors or KMPs of the company.
공시 • Sep 04Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance OfficerVanta Bioscience Limited announced the resignation of Mr. Zoheb S Sayani as the Company Secretary and Compliance officer of the Company w.e.f.15.09.2022 due to his pre-occupations.
Board Change • Jul 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jun 28Insider recently bought ₹518k worth of stockOn the 21st of June, Chandra Shekar Simhadri bought around 5k shares on-market at roughly ₹98.64 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Jun 03Full year 2022 earnings released: EPS: ₹0.14 (vs ₹0.71 in FY 2021)Full year 2022 results: EPS: ₹0.14 (down from ₹0.71 in FY 2021). Revenue: ₹101.1m (flat on FY 2021). Net income: ₹882.0k (down 80% from FY 2021). Profit margin: 0.9% (down from 4.5% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹0.71 (vs ₹1.59 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹100.4m (down 29% from FY 2020). Net income: ₹4.50m (down 55% from FY 2020). Profit margin: 4.5% (down from 7.1% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 28% per year.
Is New 90 Day High Low • Mar 03New 90-day high: ₹150The company is up 7.0% from its price of ₹140 on 03 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 3.0% over the same period.
공시 • Jan 06Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as DirectorVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the Whole Time Director of the company with effect from the close of working hours of January 4, 2021.
공시 • Jan 05Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as CEOVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the CEO of the company with effect from the close of working hours of January 04, 2021.
Is New 90 Day High Low • Dec 28New 90-day low: ₹124The company is down 31% from its price of ₹180 on 28 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 09New 90-day low: ₹134The company is down 18% from its price of ₹164 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 19% over the same period.
공시 • Nov 14Vanta Bioscience Limited Enters into Commercial Agreement with One of the Leading German Testing AgencyVanta Bioscience Limited announced that it has entered into a commercial agreement with one of the leading German Testing agency, wherein the Client has commissioned Vanta Bio to carry out Laboratory Testing Services in Biocompatibility and Analytics. The said agreement is valid for a period of 2 years. This is a major break through for the Company considering its decision to foray into Medical Devices vertical. This is not only an acknowledgement of the technical capabilities of Vanta Bio, but also validation of the world class services being provided by the Company. Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition. Expected to generate a revenue of INR 100 million-INR 150 million approx. over the period of 2 years.
Is New 90 Day High Low • Nov 04New 90-day low: ₹148The company is down 6.0% from its price of ₹157 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.
Is New 90 Day High Low • Sep 23New 90-day high: ₹170The company is up 32% from its price of ₹129 on 25 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 37% over the same period.
공시 • Jun 20Vanta Bioscience Limited to Report Fiscal Year 2020 Results on Jun 30, 2020Vanta Bioscience Limited announced that they will report fiscal year 2020 results on Jun 30, 2020